Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 67

1.

Development of Grade II Acute Graft-versus-Host Disease Is Associated with Improved Survival after Myeloablative HLA-Matched Bone Marrow Transplantation using Single-Agent Post-Transplant Cyclophosphamide.

McCurdy SR, Kanakry CG, Tsai HL, Gojo I, Smith BD, Gladstone DE, Bolaños-Meade J, Borrello I, Matsui WH, Swinnen LJ, Huff CA, Brodsky RA, Ambinder RF, Fuchs EJ, Rosner GL, Jones RJ, Luznik L.

Biol Blood Marrow Transplant. 2018 Dec 30. pii: S1083-8791(18)31700-2. doi: 10.1016/j.bbmt.2018.12.767. [Epub ahead of print]

PMID:
30599208
2.

ABVD plus rituximab versus ABVD alone for advanced stage, high-risk classical Hodgkin lymphoma: a randomized phase 2 study.

Strati P, Fanale MA, Oki Y, Turturro F, Fayad LE, Bartlett NL, Gladstone DE, Kasamon YL, Portlock CS, Wilson WH, Goy A, Younes A, Lee HJ.

Haematologica. 2019 Feb;104(2):e65-e67. doi: 10.3324/haematol.2018.199844. Epub 2018 Sep 6. No abstract available.

3.

Immune checkpoint inhibitors as a bridge to allogeneic transplantation with posttransplant cyclophosphamide.

Schoch LK, Cooke KR, Wagner-Johnston ND, Gojo I, Swinnen LJ, Imus P, Fuchs EJ, Levis M, Ambinder RF, Jones RJ, Gladstone DE.

Blood Adv. 2018 Sep 11;2(17):2226-2229. doi: 10.1182/bloodadvances.2018019208.

4.

Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia.

Kreitman RJ, Dearden C, Zinzani PL, Delgado J, Karlin L, Robak T, Gladstone DE, le Coutre P, Dietrich S, Gotic M, Larratt L, Offner F, Schiller G, Swords R, Bacon L, Bocchia M, Bouabdallah K, Breems DA, Cortelezzi A, Dinner S, Doubek M, Gjertsen BT, Gobbi M, Hellmann A, Lepretre S, Maloisel F, Ravandi F, Rousselot P, Rummel M, Siddiqi T, Tadmor T, Troussard X, Yi CA, Saglio G, Roboz GJ, Balic K, Standifer N, He P, Marshall S, Wilson W, Pastan I, Yao NS, Giles F.

Leukemia. 2018 Aug;32(8):1768-1777. doi: 10.1038/s41375-018-0210-1. Epub 2018 Jul 20.

5.

Early Fever after Haploidentical Bone Marrow Transplantation Correlates with Class II HLA-Mismatching and Myeloablation but Not Outcomes.

McCurdy SR, Muth ST, Tsai HL, Symons HJ, Huff CA, Matsui WH, Borrello I, Gladstone DE, Swinnen LJ, Cooke KR, Brodsky RA, Bolaños-Meade J, Ambinder RF, Varadhan R, Luznik L, Jones RJ, Bettinot MP, Fuchs EJ.

Biol Blood Marrow Transplant. 2018 Oct;24(10):2056-2064. doi: 10.1016/j.bbmt.2018.06.004. Epub 2018 Jun 15.

PMID:
29909152
6.

Haploidentical Bone Marrow Transplantation with Post-Transplant Cyclophosphamide Using Non-First-Degree Related Donors.

Elmariah H, Kasamon YL, Zahurak M, Macfarlane KW, Tucker N, Rosner GL, Bolaños-Meade J, Fuchs EJ, Wagner-Johnston N, Swinnen LJ, Huff CA, Matsui WH, Gladstone DE, McCurdy SR, Borrello I, Gocke CB, Shanbhag S, Cooke KR, Ali SA, Brodsky RA, DeZern AE, Luznik L, Jones RJ, Ambinder RF.

Biol Blood Marrow Transplant. 2018 May;24(5):1099-1102. doi: 10.1016/j.bbmt.2018.02.005. Epub 2018 Feb 13.

PMID:
29452245
7.

Shortened-Duration Tacrolimus after Nonmyeloablative, HLA-Haploidentical Bone Marrow Transplantation.

Kasamon YL, Fuchs EJ, Zahurak M, Rosner GL, Symons HJ, Gladstone DE, Huff CA, Swinnen LJ, Brodsky RA, Matsui WH, Borrello I, Shanbhag S, Cooke KR, Ambinder RF, Luznik L, Bolaños-Meade J, Jones RJ.

Biol Blood Marrow Transplant. 2018 May;24(5):1022-1028. doi: 10.1016/j.bbmt.2018.01.011. Epub 2018 Jan 17.

8.

Prospective study of nonmyeloablative, HLA-mismatched unrelated BMT with high-dose posttransplantation cyclophosphamide.

Kasamon YL, Ambinder RF, Fuchs EJ, Zahurak M, Rosner GL, Bolaños-Meade J, Levis MJ, Gladstone DE, Huff CA, Swinnen LJ, Matsui WH, Borrello I, Brodsky RA, Jones RJ, Luznik L.

Blood Adv. 2017;1(4):288-292. doi: 10.1182/bloodadvances.2016002766. Epub 2017 Jan 6.

9.

Pharmacokinetically-targeted dosed everolimus maintenance therapy in lymphoma patients.

Schoch LK, Asiama A, Zahurak M, Shanbhag S, Hurtt J, Sawyer K, Swinnen LJ, Wagner-Johnston N, Jones RJ, Ambinder RF, Gladstone DE.

Cancer Chemother Pharmacol. 2018 Feb;81(2):347-354. doi: 10.1007/s00280-017-3499-y. Epub 2017 Dec 13.

PMID:
29234922
10.

HLA donor-specific antibodies in allogeneic hematopoietic stem cell transplantation: challenges and opportunities.

Gladstone DE, Bettinotti MP.

Hematology Am Soc Hematol Educ Program. 2017 Dec 8;2017(1):645-650. doi: 10.1182/asheducation-2017.1.645. Review.

11.

The absolute percent deviation of IGHV mutation rather than a 98% cut-off predicts survival of chronic lymphocytic leukaemia patients treated with fludarabine, cyclophosphamide and rituximab.

Gocke CD, Gladstone DE.

Br J Haematol. 2018 Jan;180(1):7-8. doi: 10.1111/bjh.15015. Epub 2017 Dec 3. No abstract available.

PMID:
29205267
12.

Allogeneic Blood or Marrow Transplantation with Post-Transplantation Cyclophosphamide as Graft-versus-Host Disease Prophylaxis in Multiple Myeloma.

Ghosh N, Ye X, Tsai HL, Bolaños-Meade J, Fuchs EJ, Luznik L, Swinnen LJ, Gladstone DE, Ambinder RF, Varadhan R, Shanbhag S, Brodsky RA, Borrello IM, Jones RJ, Matsui W, Huff CA.

Biol Blood Marrow Transplant. 2017 Nov;23(11):1903-1909. doi: 10.1016/j.bbmt.2017.07.003. Epub 2017 Jul 12.

13.

Low immunosuppressive burden after HLA-matched related or unrelated BMT using posttransplantation cyclophosphamide.

Kanakry CG, Bolaños-Meade J, Kasamon YL, Zahurak M, Durakovic N, Furlong T, Mielcarek M, Medeot M, Gojo I, Smith BD, Kanakry JA, Borrello IM, Brodsky RA, Gladstone DE, Huff CA, Matsui WH, Swinnen LJ, Cooke KR, Ambinder RF, Fuchs EJ, de Lima MJ, Andersson BS, Varadhan R, O'Donnell PV, Jones RJ, Luznik L.

Blood. 2017 Mar 9;129(10):1389-1393. doi: 10.1182/blood-2016-09-737825. Epub 2017 Jan 3.

14.

Change in IgHV Mutational Status of CLL Suggests Origin From Multiple Clones.

Osman A, Gocke CD, Gladstone DE.

Clin Lymphoma Myeloma Leuk. 2017 Feb;17(2):97-99. doi: 10.1016/j.clml.2016.11.008. Epub 2016 Nov 21.

PMID:
28041846
15.

Comparable composite endpoints after HLA-matched and HLA-haploidentical transplantation with post-transplantation cyclophosphamide.

McCurdy SR, Kasamon YL, Kanakry CG, Bolaños-Meade J, Tsai HL, Showel MM, Kanakry JA, Symons HJ, Gojo I, Smith BD, Bettinotti MP, Matsui WH, Dezern AE, Huff CA, Borrello I, Pratz KW, Gladstone DE, Swinnen LJ, Brodsky RA, Levis MJ, Ambinder RF, Fuchs EJ, Rosner GL, Jones RJ, Luznik L.

Haematologica. 2017 Feb;102(2):391-400. doi: 10.3324/haematol.2016.144139. Epub 2016 Oct 20.

16.

Long-term systemic lupus erythematosus disease control after allogeneic bone marrow transplantation.

Gladstone DE, Petri M, Bolaños-Meade J, Dezern AE, Jones RJ, Fine D, Brodsky RA.

Lupus. 2017 Jun;26(7):773-776. doi: 10.1177/0961203316669242. Epub 2016 Sep 30.

17.

A Phase I Study of Topotecan, Carboplatin and the PARP Inhibitor Veliparib in Acute Leukemias, Aggressive Myeloproliferative Neoplasms, and Chronic Myelomonocytic Leukemia.

Pratz KW, Rudek MA, Gojo I, Litzow MR, McDevitt MA, Ji J, Karnitz LM, Herman JG, Kinders RJ, Smith BD, Gore SD, Carraway HE, Showel MM, Gladstone DE, Levis MJ, Tsai HL, Rosner G, Chen A, Kaufmann SH, Karp JE.

Clin Cancer Res. 2017 Feb 15;23(4):899-907. doi: 10.1158/1078-0432.CCR-16-1274. Epub 2016 Aug 22.

18.

A Phase 1 Study of the PARP Inhibitor Veliparib in Combination with Temozolomide in Acute Myeloid Leukemia.

Gojo I, Beumer JH, Pratz KW, McDevitt MA, Baer MR, Blackford AL, Smith BD, Gore SD, Carraway HE, Showel MM, Levis MJ, Dezern AE, Gladstone DE, Ji JJ, Wang L, Kinders RJ, Pouquet M, Ali-Walbi I, Rudek MA, Poh W, Herman JG, Karnitz LM, Kaufmann SH, Chen A, Karp JE.

Clin Cancer Res. 2017 Feb 1;23(3):697-706. doi: 10.1158/1078-0432.CCR-16-0984. Epub 2016 Aug 8.

19.

Therapeutic drug monitoring for either oral or intravenous busulfan when combined with pre- and post-transplantation cyclophosphamide.

Lombardi LR, Kanakry CG, Zahurak M, Durakovic N, Bolaños-Meade J, Kasamon YL, Gladstone DE, Matsui W, Borrello I, Huff CA, Swinnen LJ, Brodsky RA, Ambinder RF, Fuchs EJ, Rosner GL, Jones RJ, Luznik L.

Leuk Lymphoma. 2016;57(3):666-75. doi: 10.3109/10428194.2015.1071488. Epub 2015 Oct 12.

20.

Outcomes of Nonmyeloablative HLA-Haploidentical Blood or Marrow Transplantation With High-Dose Post-Transplantation Cyclophosphamide in Older Adults.

Kasamon YL, Bolaños-Meade J, Prince GT, Tsai HL, McCurdy SR, Kanakry JA, Rosner GL, Brodsky RA, Perica K, Smith BD, Gladstone DE, Swinnen LJ, Showel MM, Matsui WH, Huff CA, Borrello I, Pratz KW, McDevitt MA, Gojo I, Dezern AE, Shanbhag S, Levis MJ, Luznik L, Ambinder RF, Fuchs EJ, Jones RJ.

J Clin Oncol. 2015 Oct 1;33(28):3152-61. doi: 10.1200/JCO.2014.60.4777. Epub 2015 Aug 10.

21.

Phase II Study of Nonmyeloablative Allogeneic Bone Marrow Transplantation for B Cell Lymphoma with Post-Transplantation Rituximab and Donor Selection Based First on Non-HLA Factors.

Kanakry JA, Gocke CD, Bolaños-Meade J, Gladstone DE, Swinnen LJ, Blackford AL, Fuchs EJ, Huff CA, Borrello I, Matsui WH, Brodsky RA, Rosner GL, Shanbhag S, Luznik L, Jones RJ, Ambinder RF, Kasamon YL.

Biol Blood Marrow Transplant. 2015 Dec;21(12):2115-2122. doi: 10.1016/j.bbmt.2015.07.012. Epub 2015 Jul 14.

22.

Pre-radiation lymphocyte harvesting and post-radiation reinfusion in patients with newly diagnosed high grade gliomas.

Campian JL, Ye X, Gladstone DE, Ambady P, Nirschl TR, Borrello I, Golightly M, King KE, Holdhoff M, Karp J, Drake CG, Grossman SA.

J Neurooncol. 2015 Sep;124(2):307-16. doi: 10.1007/s11060-015-1841-y. Epub 2015 Jun 13.

23.

Risk-stratified outcomes of nonmyeloablative HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamide.

McCurdy SR, Kanakry JA, Showel MM, Tsai HL, Bolaños-Meade J, Rosner GL, Kanakry CG, Perica K, Symons HJ, Brodsky RA, Gladstone DE, Huff CA, Pratz KW, Prince GT, Dezern AE, Gojo I, Matsui WH, Borrello I, McDevitt MA, Swinnen LJ, Smith BD, Levis MJ, Ambinder RF, Luznik L, Jones RJ, Fuchs EJ, Kasamon YL.

Blood. 2015 May 7;125(19):3024-31. doi: 10.1182/blood-2015-01-623991. Epub 2015 Mar 26.

24.

Donor HLA-specific Abs: to BMT or not to BMT?

Leffell MS, Jones RJ, Gladstone DE.

Bone Marrow Transplant. 2015 Jun;50(6):751-8. doi: 10.1038/bmt.2014.331. Epub 2015 Feb 23. Review.

25.

Single-agent GVHD prophylaxis with posttransplantation cyclophosphamide after myeloablative, HLA-matched BMT for AML, ALL, and MDS.

Kanakry CG, Tsai HL, Bolaños-Meade J, Smith BD, Gojo I, Kanakry JA, Kasamon YL, Gladstone DE, Matsui W, Borrello I, Huff CA, Swinnen LJ, Powell JD, Pratz KW, DeZern AE, Showel MM, McDevitt MA, Brodsky RA, Levis MJ, Ambinder RF, Fuchs EJ, Rosner GL, Jones RJ, Luznik L.

Blood. 2014 Dec 11;124(25):3817-27. doi: 10.1182/blood-2014-07-587477. Epub 2014 Oct 14.

26.

A leukemic presentation of alveolar rhabdomyosarcoma in a 52-year-old woman without an identifiable primary tumor.

Kern JB, Hii A, Kruse MJ, Szabo Z, Argani P, Hibbard MK, Gladstone DE, Meyer C, Zheng R, Borowitz MJ, Duffield AS.

Int J Surg Pathol. 2015 Feb;23(1):75-7. doi: 10.1177/1066896914553666. Epub 2014 Oct 10.

27.

Granulocyte-macrophage colony stimulating factor (GM-CSF) enhances the clinical responses to interferon-α (IFN) in newly diagnosed chronic myeloid leukemia (CML).

Zeidner JF, Gladstone DE, Zahurak M, Matsui WH, Gocke C, Jones RJ, Smith BD.

Leuk Res. 2014 Aug;38(8):886-90. doi: 10.1016/j.leukres.2014.05.012. Epub 2014 May 29.

28.

Infusion of cryopreserved autologous lymphocytes using a standard peripheral i.v. catheter.

Gladstone DE, Davis-Sproul J, Campian J, Lemas MV, Malatyali S, Borrello I, King K, Grossman SA.

Bone Marrow Transplant. 2014 Aug;49(8):1119-20. doi: 10.1038/bmt.2014.98. Epub 2014 May 19. No abstract available.

29.

Poly(ADP-ribose) polymerase inhibitor CEP-8983 synergizes with bendamustine in chronic lymphocytic leukemia cells in vitro.

Dilley RL, Poh W, Gladstone DE, Herman JG, Showel MM, Karp JE, McDevitt MA, Pratz KW.

Leuk Res. 2014 Mar;38(3):411-7. doi: 10.1016/j.leukres.2013.12.019. Epub 2013 Dec 30.

30.

HLA-haploidentical donor lymphocyte infusions for patients with relapsed hematologic malignancies after related HLA-haploidentical bone marrow transplantation.

Zeidan AM, Forde PM, Symons H, Chen A, Smith BD, Pratz K, Carraway H, Gladstone DE, Fuchs EJ, Luznik L, Jones RJ, Bolaños-Meade J.

Biol Blood Marrow Transplant. 2014 Mar;20(3):314-8. doi: 10.1016/j.bbmt.2013.11.020. Epub 2013 Dec 1.

31.

Sustained remission and reversal of end-organ dysfunction in a patient with anaplastic myeloma.

Agrawal M, Kanakry J, Arnold CA, Suzman DL, Mathieu L, Kasamon YL, Gladstone DE, Ambinder RF, Ghosh N.

Ann Hematol. 2014 Jul;93(7):1245-6. No abstract available.

32.

Absence of post-transplantation lymphoproliferative disorder after allogeneic blood or marrow transplantation using post-transplantation cyclophosphamide as graft-versus-host disease prophylaxis.

Kanakry JA, Kasamon YL, Bolaños-Meade J, Borrello IM, Brodsky RA, Fuchs EJ, Ghosh N, Gladstone DE, Gocke CD, Huff CA, Kanakry CG, Luznik L, Matsui W, Mogri HJ, Swinnen LJ, Symons HJ, Jones RJ, Ambinder RF.

Biol Blood Marrow Transplant. 2013 Oct;19(10):1514-7. doi: 10.1016/j.bbmt.2013.07.013. Epub 2013 Jul 18.

33.

Bortezomib salvage therapy in refractory acute adult T-cell leukemia/lymphoma.

Hourigan CS, Forde PM, Ambinder RF, Gladstone DE.

Leuk Lymphoma. 2013 Nov;54(11):2563-4. doi: 10.3109/10428194.2013.780289. Epub 2013 Apr 19. No abstract available.

34.

Outcomes of related donor HLA-identical or HLA-haploidentical allogeneic blood or marrow transplantation for peripheral T cell lymphoma.

Kanakry JA, Kasamon YL, Gocke CD, Tsai HL, Davis-Sproul J, Ghosh N, Symons H, Bolaños-Meade J, Gladstone DE, Swinnen LJ, Luznik L, Fuchs EJ, Jones RJ, Ambinder RF.

Biol Blood Marrow Transplant. 2013 Apr;19(4):602-6. doi: 10.1016/j.bbmt.2013.01.006. Epub 2013 Jan 29.

35.

Partially mismatched transplantation and human leukocyte antigen donor-specific antibodies.

Gladstone DE, Zachary AA, Fuchs EJ, Luznik L, Kasamon YL, King KE, Brodsky RA, Jones RJ, Leffell MS.

Biol Blood Marrow Transplant. 2013 Apr;19(4):647-52. doi: 10.1016/j.bbmt.2013.01.016. Epub 2013 Jan 22.

36.

Maintaining hemostasis in acquired von Willebrand syndrome: a review of intravenous immunoglobulin and the importance of rituximab dose scheduling.

Kanakry JA, Gladstone DE.

Transfusion. 2013 Aug;53(8):1730-5. doi: 10.1111/trf.12017. Epub 2012 Dec 17. Review.

PMID:
23252513
37.

Phase I and pharmacologic trial of cytosine arabinoside with the selective checkpoint 1 inhibitor Sch 900776 in refractory acute leukemias.

Karp JE, Thomas BM, Greer JM, Sorge C, Gore SD, Pratz KW, Smith BD, Flatten KS, Peterson K, Schneider P, Mackey K, Freshwater T, Levis MJ, McDevitt MA, Carraway HE, Gladstone DE, Showel MM, Loechner S, Parry DA, Horowitz JA, Isaacs R, Kaufmann SH.

Clin Cancer Res. 2012 Dec 15;18(24):6723-31. doi: 10.1158/1078-0432.CCR-12-2442. Epub 2012 Oct 23.

38.

Brief intensive therapy for older adults with newly diagnosed Burkitt or atypical Burkitt lymphoma/leukemia.

Kasamon YL, Brodsky RA, Borowitz MJ, Ambinder RF, Crilley PA, Cho SY, Tsai HL, Smith BD, Gladstone DE, Carraway HE, Huff CA, Matsui WH, Bolaños-Meade J, Jones RJ, Swinnen LJ.

Leuk Lymphoma. 2013 Mar;54(3):483-90. doi: 10.3109/10428194.2012.715346. Epub 2012 Aug 17.

39.

Randomized phase II study of two schedules of flavopiridol given as timed sequential therapy with cytosine arabinoside and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia.

Karp JE, Garrett-Mayer E, Estey EH, Rudek MA, Smith BD, Greer JM, Drye DM, Mackey K, Dorcy KS, Gore SD, Levis MJ, McDevitt MA, Carraway HE, Pratz KW, Gladstone DE, Showel MM, Othus M, Doyle LA, Wright JJ, Pagel JM.

Haematologica. 2012 Nov;97(11):1736-42. doi: 10.3324/haematol.2012.062539. Epub 2012 Jun 24.

40.

Phase 1 dose-escalation trial of clofarabine followed by escalating dose of fractionated cyclophosphamide in adults with relapsed or refractory acute leukaemias.

Zeidan AM, Ricklis RM, Carraway HE, Yun HD, Greer JM, Smith BD, Levis MJ, McDevitt MA, Pratz KW, Showel MM, Gladstone DE, Gore SD, Karp JE.

Br J Haematol. 2012 Jul;158(2):198-207. doi: 10.1111/j.1365-2141.2012.09142.x. Epub 2012 May 18.

41.

Phase 2 study of rituximab-ABVD in classical Hodgkin lymphoma.

Kasamon YL, Jacene HA, Gocke CD, Swinnen LJ, Gladstone DE, Perkins B, Link BK, Popplewell LL, Habermann TM, Herman JM, Matsui WH, Jones RJ, Ambinder RF.

Blood. 2012 May 3;119(18):4129-32. doi: 10.1182/blood-2012-01-402792. Epub 2012 Feb 16.

42.

The importance of IGHV mutational status in del(11q) and del(17p) chronic lymphocytic leukemia.

Gladstone DE, Blackford A, Cho E, Swinnen L, Kasamon Y, Gocke CD, Griffin CA, Bolaños-Meade J, Jones RJ.

Clin Lymphoma Myeloma Leuk. 2012 Apr;12(2):132-7. doi: 10.1016/j.clml.2011.12.005. Epub 2012 Jan 28.

43.

Hematopoietic stem cell transplantation for chronic lymphocytic leukemia.

Gladstone DE, Fuchs E.

Curr Opin Oncol. 2012 Mar;24(2):176-81. doi: 10.1097/CCO.0b013e32834f8011. Review.

44.

Treatment of relapsing-remitting multiple sclerosis with high-dose cyclophosphamide induction followed by glatiramer acetate maintenance.

Harrison DM, Gladstone DE, Hammond E, Cheng J, Jones RJ, Brodsky RA, Kerr D, McArthur JC, Kaplin A.

Mult Scler. 2012 Feb;18(2):202-9. doi: 10.1177/1352458511419701. Epub 2011 Aug 24.

45.

Importance of immunoglobulin heavy chain variable region mutational status in del(13q) chronic lymphocytic leukemia.

Gladstone DE, Swinnen L, Kasamon Y, Blackford A, Gocke CD, Griffin CA, Meade JB, Jones RJ.

Leuk Lymphoma. 2011 Oct;52(10):1873-81. doi: 10.3109/10428194.2011.585529. Epub 2011 Aug 18.

46.

High-dose cyclophosphamide and rituximab without stem cell transplant: a feasibility study for low grade B-cell, transformed and mantle cell lymphomas.

Gladstone DE, Bolaños-Meade J, Huff CA, Zahurak M, Flinn I, Borrello I, Luznik L, Fuchs E, Kasamon Y, Matsui W, Powell J, Levitsky H, Brodsky RA, Ambinder R, Jones RJ, Swinnen LJ.

Leuk Lymphoma. 2011 Nov;52(11):2076-81. doi: 10.3109/10428194.2011.594191. Epub 2011 Jul 14.

47.

High-dose chemotherapy and multiple sclerosis.

Harrison D, Gladstone DE.

Curr Opin Oncol. 2011 Mar;23(2):221-6. doi: 10.1097/CCO.0b013e328342c6b3. Review.

48.

High-dose cyclophosphamide for moderate to severe refractory multiple sclerosis: 2-year follow-up (investigational new drug No. 65863).

Gladstone DE, Peyster R, Baron E, Friedman-Urevich S, Sibony P, Melville P, Gottesman M.

Am J Ther. 2011 Jan;18(1):23-30. doi: 10.1097/MJT.0b013e3181b3ad95.

PMID:
19770795
49.

Refractory Waldenström's macroglobulinaemia responsive to 2-chlorodeoxyadenosine and mycophenolate mofetil.

Gladstone DE.

Leuk Res. 2008 Sep;32(9):1487-8. doi: 10.1016/j.leukres.2008.02.015. Epub 2008 Apr 18. No abstract available.

PMID:
18378308
50.

High dose cyclophosphamide preferentially targets naïve T (CD45/CD4/RA+) cells in CIDP and MS patients.

Gladstone DE, Golightly MG, Brannagan TH 3rd.

J Neuroimmunol. 2007 Oct;190(1-2):121-6. Epub 2007 Sep 14.

PMID:
17854912

Supplemental Content

Loading ...
Support Center